Immatics N.V. filings document a foreign private issuer whose regulatory record centers on clinical-stage oncology development, financing capacity and public-company governance. Form 6-K reports furnish press releases, interim reports and investor presentations covering PRAME cell therapy and TCR bispecific programs, including anzu-cel, IMA203CD8, IMA402 and IMA401 MAGEA4/8, along with financial results and business updates.
The filings also include incorporation-by-reference language for Form S-8 and Form F-3 registration statements, leadership and governance disclosures, forward-looking clinical and regulatory risk statements, and capital-structure or shareholder matters tied to the company's Nasdaq-traded security.
Immatics N.V. director Michael G. Atieh received a grant of stock options covering 48,000 underlying ordinary shares. The options have an exercise price of $9.09 per share, expire on June 15, 2036, and vest 100% on the first anniversary of the June 16, 2025 grant date.
Immatics N.V. director Carter Paul Rutherford received a grant of stock options covering 48,000 Ordinary Shares. The options have an exercise price of $9.09 per share and expire on June 15, 2036. According to the footnote, the options vest 100% on the first anniversary of the grant date, June 16, 2026. This is a compensation-related award, not an open-market share purchase or sale.
Immatics N.V. director Eliot Forster received a grant of stock options covering 48,000 ordinary shares. The options have an exercise price of $9.09 per share and expire on June 15, 2036. They vest 100% on the first anniversary of the grant date, June 16, 2026, and result in total option holdings of 48,000 derivative securities reported in this filing.
Immatics N.V. director Peter Alan Chambre received a grant of stock options as part of his compensation. He was awarded 48,000 Stock Options (Right to Buy), each allowing purchase of one ordinary share at an exercise price of $9.09 per share.
The options vest 100% on the first anniversary of the grant date, June 16, 2026, and expire on June 15, 2036. Following this award, his reported holdings in this option grant total 48,000 derivative securities, with no shares bought or sold in the market in this filing.
Immatics N.V. director Heather L. Mason received a grant of stock options as part of her compensation. She was awarded options to buy 48,000 ordinary shares at an exercise price of $9.09 per share. These options vest 100% on the first anniversary of the grant date, June 16, 2026, and expire on June 15, 2036. After this grant, she holds 48,000 stock options directly.
Immatics N.V. reported an insider equity award linked to its board of directors. Options covering 48,000 ordinary shares were granted on June 16, 2026 with an exercise price of $9.09 per share and expire on June 15, 2036.
The option vests in full on the first anniversary of the grant date. The award relates to director compensation for Adam Stone’s board service, and Perceptive Advisors LLC reports an indirect pecuniary interest through a management fee offset arrangement, while disclaiming beneficial ownership except to that indirect interest.
Immatics N.V. director Mathias Hothum received a grant of 48,000 stock options to purchase Ordinary Shares at an exercise price of $9.09 per share. These options vest 100% on June 16, 2026 and expire on June 15, 2036, leaving him holding 48,000 derivative securities directly.
This is a compensation-related award, not an open-market stock purchase or sale.
Immatics N.V. held its Annual General Meeting of Shareholders, where all voting items on the agenda were approved by the required majorities. The meeting was duly convened under Dutch law and the company’s articles of association.
Approximately 64.07% of the company’s issued share capital was represented at the meeting, indicating a solid level of shareholder participation. The minutes of the AGM are furnished as an exhibit, and this report (other than the exhibit itself) is incorporated by reference into Immatics’ existing Form S-8 and Form F-3 registration statements.
Immatics N.V. has called its annual general meeting for 18 June 2026 at 16:00 CEST in Amsterdam, with a record date of 21 May 2026. Shareholders on the record date may attend and vote in person or by proxy, with detailed procedures for registered and beneficial owners.
Key agenda items include adopting the statutory annual accounts for the year ended 31 December 2025, discussing dividend and reservation policy, and granting discharge to directors. Shareholders will vote on reappointing Harpreet Singh Jasuja as executive director and two non-executive directors through the 2029 AGM, extending the Board’s authority for share repurchases for 18 months from the AGM, and approving a 2026 stock option and incentive plan covering up to 6,448,836 ordinary shares. Appointment of PricewaterhouseCoopers Accountants N.V. as auditor for financial year 2026 is also proposed.
Immatics N.V. reports extensive early‑stage clinical data across its PRAME‑ and MAGEA4/8‑targeted pipeline, highlighting activity in multiple hard‑to‑treat solid tumors. The 6‑K centers on updated Phase 1/1b results for IMA203CD8, IMA401 and anzu‑cel presented at the 2026 ASCO meeting.
For anzu‑cel in advanced melanoma, confirmed objective response rate was 56% (18/32) with overall response rate 64% (21/33) and disease control rate 91% (30/33). Median duration of response reached 14.6 months, median progression‑free survival 6.1 months and median overall survival 16.2 months, with some responses exceeding three years.
IMA203CD8 showed dose‑dependent anti‑tumor activity in heavily pretreated gynecologic cancers and synovial sarcoma, with manageable cytokine release syndrome and no treatment‑related Grade 5 events. IMA401, a MAGEA4/8 TCR bispecific, demonstrated a favorable tolerability profile and clinical activity at the 1–2 mg recommended Phase 2 dose, supporting a new IMA401/IMA402 combination cohort in squamous non‑small cell lung cancer. All datasets are preliminary and drawn from ongoing early‑phase trials.